Bonti Overview

  • Founded
  • 2015
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 10
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $285M
Latest Deal Amount

Bonti General Information

Description

Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company develops botulinum neurotoxin for the treatment of muscle hyperactivity, the root cause of musculoskeletal pain in both post-surgical and non-surgical settings, enabling patients to have a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products.

Contact Information

Website
Formerly Known As
Endurance Biotech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • 4921 Birch Street
  • Suite 120
  • Newport Beach, CA 92660
  • United States
+1 (949) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Bonti Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Oct-2018 $285M 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 23-Jan-2018 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 10-Apr-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
2. Debt - General 01-Dec-2015 $2M $10.9M Completed Startup
1. Early Stage VC (Series A) 28-Aug-2015 $8.9M $8.9M 000.00 Completed Startup
To view Bonti’s complete valuation and funding history, request access »

Bonti Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00 00 00 00 00.000
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 7,451,478 $0.000100 8% $1.2 $1.2 1x $1.2 21.14%
To view Bonti’s complete cap table history, request access »

Bonti Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company
Drug Discovery
Newport Beach, CA
10 As of 2018
000.00
0000 0000-00-00
000000&0 000.00

0000000

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000000
Austin, TX
00 As of 0000
0000
000000000 0000

0000 000

e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000 000000000
La Jolla, CA
00 As of 0000
00.000
000 0000-00-00
00000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bonti Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genprex Formerly VC-backed Austin, TX 00 0000 000000000 0000
0000 0000000000000 Venture Capital-Backed La Jolla, CA 00 00.000 00000000000 00.000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed San Carlos, CA 0 000.00 0000000000 0 000.00
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

Bonti Executive Team (7)

Name Title Board Seat Contact Info
Fauad Hasan Co-Founder, President, Chief Executive Officer & Board Member
David Ramsay Co-Founder, Chief Financial Officer & Board Member
Wajdie Ahmad Chief Operating Officer & Co-Founder
Mike Jarpe Ph.D Executive Vice President of Drug Development & Co-Founder
Susan Abushakra MD Chief Medical Officer & Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

Bonti Board Members (8)

Name Representing Role Since
David Ramsay Bonti Co-Founder, Chief Financial Officer & Board Member 000 0000
Fauad Hasan Bonti Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
Leonard Brandt Bonti Board Member 000 0000
Tom Albright Bonti Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Bonti Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bonti Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
City Hill Ventures Venture Capital Minority 000 0000 000000 0
Colt Ventures Venture Capital Minority 000 0000 000000 0
Highlight Capital Venture Capital Minority 000 0000 000000 0
Hunt Technology Ventures Other Minority 000 0000 000000 0
JMCR Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »